Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Palliative Radiotherapy in Gastroesophageal Cancer
NCT02830594Phase 2Completed
- Sponsor
- City of Hope
- Start
- Dec 2016
- Primary completion
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in gastric adenocarcinoma, gastric squamous cell carcinoma (GSCC), gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC), Esophageal Squamous Cell Carcinoma (ESCC), sponsored by City of Hope. Started Dec 2016; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinomagastric squamous cell carcinoma (GSCC)gastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT02830594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02830594.